Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-30 22:27:57 - browse：6

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Texas board proposes rules on abortion law emergency exemption

WSS

Biotech investment managers search for lucrative opportunities

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Mirador, a new biotech startup, launches with $400 million

How AI helped researchers track recovery from depression

CommonSpirit Health keeps growing, even as it loses money

EpiPen alternative approval delay highlights citizen petition issue

entertainment

Wikipedia

focus

After affirmative action ruling, medical educators look to 'holistic review'

It's been 20 years since Dolly the sheep. Where's my clone?

What does generative AI mean for health care? We asked experts

STAT Virtual Event: Putting AI to the Test

Tori Bowie and the unacceptable rates of Black maternal death

Medical student insurance fails on mental health care coverage

Moonlake's readout produced a cash windfall. Risks remain

Readout LOUD podcast, live from the STAT Breakthrough Summit East

United colonoscopy coverage change 'may cost lives,' doctors say

Emergency workers more likely to restrain Black patients: study

focus

Pfizer, Moderna say biotech, pharma drug development is a sprint

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Thermo Fisher plant for manufacturing gene therapies to expand

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

How Vertex's cystic fibrosis drug is changing patients' lives

It's been 20 years since Dolly the sheep. Where's my clone?

focus

focus

focus

entertainment